Western blot analyses were performed to evaluate COPD-related targets (EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2) involved in the therapeutic effects of luteolin on COPD. The gene discussed is APP; the disease is chronic obstructive pulmonary disease.